Literature DB >> 17712052

Therapeutic drug monitoring in CML patients on imatinib.

Carolyn Blasdel, Merrill J Egorin, Theodore F Lagattuta, Brian J Druker, Michael W Deininger.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17712052     DOI： 10.1182/blood-2007-03-079871

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  8 in total

1.  Participation of CYP2C8 and CYP3A4 in the N-demethylation of imatinib in human hepatic microsomes.

Authors:  Noelia Nebot; Severine Crettol; Fabrizio d'Esposito; Bruce Tattam; David E Hibbs; Michael Murray
Journal:  Br J Pharmacol       Date:  2010-11       Impact factor: 8.739

Review 2.  Practical guidelines for therapeutic drug monitoring of anticancer tyrosine kinase inhibitors: focus on the pharmacokinetic targets.

Authors:  Huixin Yu; Neeltje Steeghs; Cynthia M Nijenhuis; Jan H M Schellens; Jos H Beijnen; Alwin D R Huitema
Journal:  Clin Pharmacokinet       Date:  2014-04       Impact factor: 6.447

3.  Determination of the Cut-off Value for Imatinib Plasma Levels Linked to Occurrence of Bone Pain in CML Patients.

Authors:  Marwa S Hamza; Samia A Shouman; Raafat Abdelfattah; Heba S Moussa; Mervat M Omran
Journal:  Drug Des Devel Ther       Date:  2022-05-30       Impact factor: 4.319

4.  Imatinib plasma levels: correlation with clinical benefit in GIST patients.

Authors:  N Widmer; L A Decosterd; C Csajka; M Montemurro; A Haouala; S Leyvraz; T Buclin
Journal:  Br J Cancer       Date:  2010-02-23       Impact factor: 7.640

Review 5.  Pharmacokinetic considerations for new targeted therapies.

Authors:  S D Baker; S Hu
Journal:  Clin Pharmacol Ther       Date:  2008-12-17       Impact factor: 6.875

6.  Relationship between an effective dose of imatinib, body surface area, and trough drug levels in patients with chronic myeloid leukemia.

Authors:  Tatsuya Kawaguchi; Akinobu Hamada; Chie Hirayama; Reiko Nakashima; Takeru Nambu; Yuji Yamakawa; Hiroshi Watanabe; Kentaro Horikawa; Hiroaki Mitsuya; Hideyuki Saito
Journal:  Int J Hematol       Date:  2009-04-25       Impact factor: 2.490

7.  Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability.

Authors:  N Widmer; L A Decosterd; S Leyvraz; M A Duchosal; A Rosselet; M Debiec-Rychter; C Csajka; J Biollaz; T Buclin
Journal:  Br J Cancer       Date:  2008-05-06       Impact factor: 7.640

8.  Therapeutic drug monitoring for imatinib: Current status and Indian experience.

Authors:  Brijesh Arora; Vikram Gota; Hari Menon; Manju Sengar; Reena Nair; Pankaj Patial; S D Banavali
Journal:  Indian J Med Paediatr Oncol       Date:  2013-07
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.